A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

7.2K views

⸱

DOI:

10.3791/56256

⸱

February 23rd, 2018

In This Article

Summary

We describe a method to measure the activation of Fc-mediated effector functions by antibodies that target the influenza virus hemagglutinin. This assay can also be adapted to assess the ability of monoclonal antibodies or polyclonal sera targeting other viral surface glycoproteins to induce Fc-mediated immunity.

Abstract

Antibodies play a crucial role in coupling the innate and adaptive immune responses against viral pathogens through their antigen binding domains and Fc-regions. Here, we describe how to measure the activation of Fc effector functions by monoclonal antibodies targeting the influenza virus hemagglutinin with the use of a genetically engineered Jurkat cell line expressing an activating type 1 Fc-FcγR. Using this method, the contribution of specific Fc-FcγR interactions conferred by immunoglobulins can be determined using an in vitro assay.

Introduction

Immunity provided by the seasonal influenza vaccine has traditionally been assessed by the hemagglutination inhibition (HI) assay1, which measures the presence of antibodies that target the receptor binding site of the hemagglutinin. These HI-active antibodies can confer sterilizing immunity, but are generally narrow in their breadth of protection, providing immunity to only a select few strains of influenza virus. The isolation and characterization of broadly reactive monoclonal antibodies that recognize the hemagglutinin (HA) suggest the development of a universal influenza vaccine is within reach2,

Access restricted. Please log in or start a trial to view this content.

Protocol

The experiments preformed in this manuscript were done following Icahn School of Medicine’s institutional code of ethics and regulations.

1. Expression of Influenza Virus Hemagglutinin via Transfection or Infection

Transfection:

  1. Plate Human Embryonic Kidney (HEK 293T) cells at a density of 2 x 104 cells/well in a white tissue culture treated 96-well plate and let it sit for 4 h in a 37 °C incubator (with 5% CO2).
  2. Transfect cells with 100 ng of DNA coding for viral hemagglutinin and 0.2 μL of transfection reagent per well....

Access restricted. Please log in or start a trial to view this content.

Results

We demonstrated that a stalk-specific mAb, 6F12, but not head-specific a head-specific mAb, PY102, was able to activate primary natural killer cells by upregulating CD107a and interferon γ19. To model the ability of a stalk-specific antibody to activate primary human NK cells, we show that a stalk-specific mAb, 6F12, can robustly activate the modified Jurkat cell expressing the murine FcγRIV by ~14-fold. On the other hand, the head-specific mAb, PY102 and the control IgG do not (

Access restricted. Please log in or start a trial to view this content.

Discussion

The method described here allows the user to measure the ability of an HA-specific monoclonal antibody to engage the murine FcγRIV. The target antigen, influenza virus hemagglutinin, is expressed on the surface of cells after infection by virus or transfection of plasmid DNA. The assay is further amenable to using different surface-expressed viral proteins in combination with other FcγRs (humans or murine). Additionally, we have used sera samples to assess the ability of antibodies in a polyclonal context to in.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Authors declare no conflicts of interest.

Acknowledgements

This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under CEIRS contract P01AI097092-04S1 (P.E.L.).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
A549 cells ATCCCCL-185Adenocarcinomic human alveolar basal epithelial cells
HEK 293T cellsATCCCRL-3216Human embryonic kidney cells
Lipofectamine 2000Life Technologies 11668019Transfection reagent
1X Opti-MEM Reduced Serum MediumThermoFisher Scientific51985-034
White tissue culture treated 96-well plateCorning, Inc. 3917Assay plates
10X MEMGibco11430-030
Jurkat cell expressing murine FcgRIVPromegaM1201Kit provides includes cells, Bio-Glo Luciferase assay system, 1X RPMI and low IgG serum
Jurkat cell expressing human FcgRIIIaPromegaG7010Kit provides includes cells, Bio-Glo Luciferase assay system, 1X RPMI and low IgG serum
Jurkat cell expressing human FcgRIIaPromegaG9901Kit provides includes cells, Bio-Glo Luciferase assay system, 1X RPMI and low IgG serum
LuminometerBioTekSynergy H1 Multi-Mode readerLuminescence plate reader
Bio-Glo Luciferase Assay SystemPromegaG7940Contains luciferase assay buffer and luciferase assay substrate
Madin Darby canine kidney cellsATCCCCL-34Canine kidney cells

References

  1. Hobson, D., Curry, R. L., Beare, A. S., Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hygiene. 70 (04), 767-777 (1972).
  2. Throsby, M., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Influenza Hemagglutinin AntibodiesADCC Assay MethodJurkat Fc Receptor CellsHemagglutinin Expression TransfectionLuciferase Substrate DetectionAntibody-Dependent CytotoxicityFc Gamma Receptor ActivationIn Vitro Immunity AssayEffector Cell Activation